José Baselga

Weatherford College — United States

Medicine · Health Sciences

109h-index73.8kcitations368works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(168), Cancer Treatment and Pharmacology(87), Monoclonal and Polyclonal Antibodies Research(73), Lung Cancer Treatments and Mutations(62), Colorectal Cancer Treatments and Studies(45)

Publications368 total

Editor’s Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis
Clinical Cancer Research·2024Open Access
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
International Journal of Molecular Sciences·2020· 41 citedOpen Access
Abstract P3-03-01: Double <i>PIK3CA</i> mutations in <i>cis</i> drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer
Cancer Research·2020
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
Cancer Discovery·2020· 156 citedOpen Access
Author Correction: Tumour lineage shapes BRCA-mediated phenotypes
Nature·2019· 20 citedOpen Access
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
European Journal of Cancer·2019· 20 citedOpen Access
Abstract 4891: Gene expression analysis of paired baseline (BL) and on-treatment tumor samples from FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) plus paclitaxel (PAC) in early triple-negative breast cancer (eTNBC)
Cancer Research·2019
Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer
Bioinformatics, Convergence Science, and Systems Biology·2019
Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
Annals of Oncology·2019· 7 citedOpen Access
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Clinical Cancer Research·2019· 56 cited
Abstract P6-18-30: Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
Cancer Research·2019· 1 cited
Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses
Cancer Research·2019· 9 cited
Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Clinical Cancer Research·2019· 1 citedOpen Access
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Clinical Cancer Research·2019· 120 citedOpen Access
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma
2019· 26 citedOpen Access
Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
Annals of Oncology·2019Open Access
Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis
Blood·2018· 6 cited
A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation
EMBO Molecular Medicine·2018· 263 citedOpen Access
Failure to Accurately Disclose Conflicts of Interest in Articles Published in <i>JAMA Oncology</i>
JAMA Oncology·2018· 2 citedOpen Access
Failure to Disclose Conflict of Interest in Article Published in <i>JAMA</i> on Detection of Cancer-Related Genes
JAMA·2018· 6 cited
page 1 of 19Next →

Frequent Co-authors

Federico Rojo(7), Josep Tabernero(6), Javier Cortés(6), John Mendelsohn(6), Maurizio Scaltriti(6), Marta Guzmán(6), Joan Seoane(5), Matthew Meyerson(4), Luca Gianni(4), Joan Albanell(4), Violeta Serra(4), Joaquı́n Arribas(4), Larry Norton(3), Rameen Beroukhim(3), Michael S. Lawrence(3), Stacey Gabriel(3), Levi A. Garraway(3), Gad Getz(3), Masahiro Fukuoka(3), A. Feyereislova(3)